Literature DB >> 9579894

Safety of intrahippocampal depth electrodes for presurgical evaluation of patients with intractable epilepsy.

G Fernández1, A Hufnagel, D Van Roost, C Helmstaedter, H K Wolf, J Zentner, J Schramm, C E Elger.   

Abstract

PURPOSE: Intracerebral depth electrodes are used in preoperative evaluation of selected patients with intractable epilepsies. In spite of their usefulness, safety of depth electrodes is disputed, and the number of insertions is decreasing. This study examined retrospectively possible deleterious effects such as perioperative complications, induction of epileptogenesis, and neuropsychologic deficits.
METHODS: Clinical course and neuroradiologic findings of 115 patients with bilaterally inserted longitudinal intrahippocampal depth electrodes (IDEs) were analyzed. Hippocampal resection specimens were examined histopathologically. To detect newly developed epileptogenic areas, EEG recordings, seizure control, and semiology after standardized resection procedures were compared between patients who received IDEs and those who did not. To demonstrate functional deficits caused by IDE insertion into an unaffected hippocampus of the speech-dominant hemisphere, changes of verbal learning and memory performances before and after right amygdalohippocampectomy were compared between patients evaluated with and without IDEs.
RESULTS: Five significant complications without any permanent neurologic deficit were noted, and only one was specifically linked to IDE insertion. The tissue damage associated with the insertion was minimal and sharply circumscribed. No differences of seizure outcome after standardized resections were identified between patients with and without IDEs. In postoperative EEG recordings, there was no evidence of new epileptogenic areas. No verbal memory deficit caused by IDE implantation into the hippocampus of the speech-dominant hemisphere was detectable.
CONCLUSIONS: Results indicate that it is safe to implant these IDEs in selected patients.

Entities:  

Mesh:

Year:  1997        PMID: 9579894     DOI: 10.1111/j.1528-1157.1997.tb01258.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

1.  Surgery after intracranial investigation with subdural electrodes in patients with drug-resistant focal epilepsy: outcome and complications.

Authors:  Roberta Morace; Giancarlo Di Gennaro; Angelo Picardi; Pier Paolo Quarato; Antonio Sparano; Addolorata Mascia; Giulio Nicolò Meldolesi; Liliana Graciela Grammaldo; Marco De Risi; Vincenzo Esposito
Journal:  Neurosurg Rev       Date:  2012-03-22       Impact factor: 3.042

2.  Extraventricular long-axis cannulation of the hippocampus: technical considerations.

Authors:  Chengyuan Wu; Michael J LaRiviere; Nealen Laxpati; James J Evans; Robert E Gross; Ashwini D Sharan
Journal:  Neurosurgery       Date:  2014-06       Impact factor: 4.654

3.  A computer-generated stereotactic "Virtual Subdural Grid" to guide resective epilepsy surgery.

Authors:  Kevin Morris; Terence J O'Brien; Mark J Cook; Michael Murphy; Stephen C Bowden
Journal:  AJNR Am J Neuroradiol       Date:  2004-01       Impact factor: 3.825

4.  Safety profile of intracranial electrode implantation for video-EEG recordings in drug-resistant focal epilepsy.

Authors:  Bertrand Mathon; Stéphane Clemenceau; Dominique Hasboun; Marie-Odile Habert; Hayat Belaid; Vi-Huong Nguyen-Michel; Virginie Lambrecq; Vincent Navarro; Sophie Dupont; Michel Baulac; Philippe Cornu; Claude Adam
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

Review 5.  Presurgical evaluation and surgical treatment of medically refractory epilepsy.

Authors:  Adrian M Siegel
Journal:  Neurosurg Rev       Date:  2003-10-28       Impact factor: 3.042

6.  Complications to invasive epilepsy surgery workup with subdural and depth electrodes: a prospective population-based observational study.

Authors:  Emelie Hedegärd; Johan Bjellvi; Anna Edelvik; Bertil Rydenhag; Roland Flink; Kristina Malmgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-29       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.